May 17, 2021

Convalescent Plasma in Patients Admitted to Hospital with COVID-19 (RECOVERY): A Randomised Controlled, Open-Label, Platform Trial

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): treatment

• Among patients hospitalized with COVID-19, convalescent plasma treatment did not improve 28-day mortality (RR = 1.0), time to hospital discharge (RR = 0.99), or result in a significant difference in the proportion of patients who either received invasive mechanical ventilation or died (RR = 0.99), according to results from the RECOVERY trial in the UK. 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days, and the mortality rate ratio was similar among all prespecified subgroups of patients, including those who did not have detectable SARS-CoV-2 antibodies at randomization. [EDITORIAL NOTE: A pre-print related to this manuscript was summarized on March 11, 2021].

Horby et al. (May 14, 2021). Convalescent Plasma in Patients Admitted to Hospital with COVID-19 (RECOVERY): A Randomised Controlled, Open-Label, Platform Trial. The Lancet. https://doi.org/10.1016/S0140-6736(21)00897-7